Company: Sun Pharmaceutical Industries Ltd. Category: Broker Research

Sun Pharmaceutical Industries (SPIL) is India’s largest and the world’s fifth-largest generic pharmaceutical company.
March 5, 2019, 2:21 p.m.

The USFDA conducted an inspection at SUNP’s Mohali plant during 10-14 September 2018, and issued Form 483 with two observations.
Sept. 19, 2018, 11:04 a.m.

Sun Pharmaceutical Industries (SPIL) has received the US Food and Drug Administration or USFDA’s approval for Xelpros - a novel drug formulation of Xalatan (latanoprost) - the most widely prescribed treatment for Glaucoma.
Sept. 17, 2018, 11:29 a.m.

US FDA recently conducted an inspection at SUNP’s Halol plant from 27-31 August and issued Form-483 with six observations.
Sept. 7, 2018, 10:38 a.m.

SUN pharma is largest pharma company in India , 30% of Company’s sales comes from India , 70% business comes from Export.
July 23, 2018, 10:42 a.m.

We expect Seciera to be US$400mn to US$600mn peak sales opportunity for Sun Pharmaceutical Industries (Sun Pharma).
March 12, 2018, 12:33 p.m.
Author : Nirmal Bang | Publisher:

Sun pharma received three observations post USFDA visit of the Halol plant in February 2018. The three observations are neither linked to data integrity nor are linked to any repeat observations.
March 6, 2018, 1:53 p.m.

The US Food and Drug Administration (US FDA) inspected Sun Pharma’s (SUNP) Halol plant from 12-23 February 2018.
March 6, 2018, 1:13 p.m.

Sun Pharmaceuticals: Maintain Reduce, says Equirus Research
Sept. 26, 2017, 4:24 p.m.

Sun Pharmaceutical Industries: Weak Q1FY18 quarter; pain to continue - Geojit
Sept. 15, 2017, 4:27 p.m.

  • 1